{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:21:12Z","timestamp":1791937272425,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"15","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.vaccine.2014.01.019","type":"journal-article","created":{"date-parts":[[2014,2,6]],"date-time":"2014-02-06T13:00:26Z","timestamp":1391691626000},"page":"1745-1753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study"],"prefix":"10.1016","volume":"32","author":[{"given":"Roman","family":"Chlibek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Smetana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlis","family":"Pauksens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anneke R.","family":"Van den Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Richardus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Ledent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Heineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.01.019_bib0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"issue":"RR-5","key":"10.1016\/j.vaccine.2014.01.019_bib0010","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2014.01.019_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2014.01.019_bib0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.vaccine.2014.01.019_bib0025","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"issue":"12 Suppl. 8","key":"10.1016\/j.vaccine.2014.01.019_bib0030","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/WNL.45.12_Suppl_8.S41","article-title":"Immunization to reduce the frequency and severity of herpes zoster and its complications","volume":"45","author":"Oxman","year":"1995","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.vaccine.2014.01.019_bib0035","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2014.01.019_bib0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2014.01.019_bib0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2014.01.019_bib0050","doi-asserted-by":"crossref","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"issue":"19","key":"10.1016\/j.vaccine.2014.01.019_bib0055","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.00533-06","article-title":"Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection","volume":"80","author":"Berarducci","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.01.019_bib0060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0912373107","article-title":"Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection","volume":"107","author":"Berarducci","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2014.01.019_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev.mi.44.100190.000423","article-title":"Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking","volume":"44","author":"Grose","year":"1990","journal-title":"Annu Rev Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.01.019_bib0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(05)70312-3","article-title":"Immune responses to varicella-zoster virus","volume":"10","author":"Arvin","year":"1996","journal-title":"Infect Dis Clin North Am"},{"issue":"20","key":"10.1016\/j.vaccine.2014.01.019_bib0075","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.01.019_bib0080","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.01.019_bib0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-1759(01)00416-1","article-title":"Use of overlapping peptide mixtures as antigens for cytokine flow cytometry","volume":"255","author":"Maecker","year":"2001","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2014.01.019_bib0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1026403724413","article-title":"Immunofluorescence analysis of T-cell responses in health and disease","volume":"20","author":"Maecker","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2014.01.019_bib0095","series-title":"Design of experiments: ranking and selection","article-title":"Ranking and selection and multiple comparisons with the best","author":"Hsu","year":"1984"},{"key":"10.1016\/j.vaccine.2014.01.019_bib0100","series-title":"Multiple comparisons: theory and methods","author":"Hsu","year":"1996"},{"key":"10.1016\/j.vaccine.2014.01.019_bib0105","series-title":"48th Infectious Diseases Society of America (IDSA) annual meeting","article-title":"An adjuvanted VZV subunit vaccine is well-tolerated and more immunogenic than a live varicella vaccine in adults","author":"Leroux-Roels","year":"2010"},{"key":"10.1016\/j.vaccine.2014.01.019_bib0110","series-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.040","article-title":"VZV: immunobiology and host response","author":"Arvin","year":"2007"},{"issue":"3","key":"10.1016\/j.vaccine.2014.01.019_bib0115","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/315347","article-title":"Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression","volume":"181","author":"Asanuma","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2014.01.019_bib0120","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2014.01.019_bib0125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","article-title":"Age-related changes in lymphocyte development and function","volume":"5","author":"Linton","year":"2004","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.01.019_bib0130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cid\/ciq160","article-title":"An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers","volume":"52","author":"Van Braeckel","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2014.01.019_bib0135","doi-asserted-by":"crossref","first-page":"e6465","DOI":"10.1371\/journal.pone.0006465","article-title":"Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area","volume":"4","author":"Polhemus","year":"2009","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T16:57:02Z","timestamp":1538845022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":27,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0264410X14000516"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}